Quick way to Jinx Things…

Stormin..Live Quote

We’re still not sure how to pronounce it…but Wall Street likes it.

Where does this volume come from..18 thousand to 100 million!

News Archive

Unicycive Therapeutics (UNCY) $2.73. We’re now up 249%.

Unicycive (UNCY) Shoots and Scores, We’re up 126%.

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers. Unicyive (UNCY). We’re Down 30%

Adding Unicycive (UNCY) $0.75 to the Watch List.

More Brokers Chime In.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:

[email protected]
(650) 900-5470

Anne Marie Fields
Stern Investor Relations
[email protected]

SOURCE: Unicycive Therapeutics, Inc.